METHODS: A systematic literature on randomized controlled trials (RCTs) of prescriptions containing astragalus in the treatment of RILI by Pubmed, Embase, Web of Science, Cochrane Library, China Biomedical Literature Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, WANFANG Database. The retrieval time is from the establishment of the database to January 18, 2022. Meta-analysis, heterogeneity test and sensitivity analysis were performed on eligible RCTs using Revman 5.4 software and STATA 17.0 software, and a \"funnel plot\" was used to analyze potential publication bias.
RESULTS: A total of 25 RCTs were included, including 1762 patients, and the most widely used drugs were heat-clearing and detoxifying, yin-nourishing and qi-nourishing. The prescriptions containing astragalus can significantly reduce the total incidence of RILI (P < .01), improve the total effective rate and cure rate of RILI (P < .01), improve the quality of life of patients, alleviate breathing difficulties and reduce the expression of inflammatory factors (P < .01), and no adverse reactions related to TCM treatment were reported.
CONCLUSIONS: The traditional Chinese medicinal preparation containing astragalus can effectively alleviate the clinical symptoms of RILI, reduce the toxic side effects, and is safe to use in clinic.
方法:Pubmed撰写的关于含有黄芪的处方治疗RILI的随机对照试验(RCT)的系统文献,Embase,WebofScience,科克伦图书馆,中国生物医学文献数据库,中国国家知识基础设施,中国科技期刊数据库,万方数据库。检索时间从数据库建立到2022年1月18日。Meta分析,采用Revman5.4软件和STATA17.0软件对符合条件的RCT进行异质性检验和敏感性分析,并使用“漏斗图”分析潜在的发表偏倚。
结果:共包括25项RCT,包括1762名患者,最广泛使用的药物是清热解毒,滋阴养气。含黄芪的方剂能显著降低RILI的总发生率(P<0.01),提高RILI的总有效率和治愈率(P<0.01),提高患者的生活质量,减轻呼吸困难,减少炎症因子的表达(P<0.01),未报告与中医治疗相关的不良反应。
结论:含黄芪的中药制剂能有效缓解RILI的临床症状,减少毒副作用,并且在临床上使用是安全的。